Nurix Therapeutics Announces Multiple Presentations at the American Association for Cancer Research (AACR) 2025 Annual Meeting

Core Insights - Nurix Therapeutics, Inc. is set to present preclinical data from its DEL-AI platform and various degrader programs at the AACR 2025 Annual Meeting, highlighting its focus on targeted protein degradation medicines [1][8] Presentation Details - The oral presentation titled "DEL-AI: Proteome-wide in silico screening of multi-billion compound libraries using machine learning foundation models" will be presented by Paul Novick, Ph.D. on April 28, 2025 [2] - Another oral presentation titled "Identification of selective, orally bioavailable Aurora A degraders for treatment of pediatric and adult cancers" will be presented by Ryan Rountree, Ph.D. on April 29, 2025 [2] - The poster presentation titled "NRX-0305: a pan-mutant BRAF degrader with broad preclinical efficacy, brain penetrance, and synergistic potential with MEKi across class 1/2/3 BRAF-mutant cancers" will be presented by Alexandra 'Sasha' Borodovsky, Ph.D. on April 28, 2025 [3] - The poster presentation titled "NX-5948 is a CNS-penetrant catalytic Bruton's tyrosine kinase (BTK) degrader that breaks established design rules for CNS drugs" will be presented by Wylie Palmer, Ph.D. on April 30, 2025 [3] About DEL-AI - DEL-AI is Nurix's proprietary discovery platform that utilizes advanced machine learning for drug discovery, enabling rapid generation of degraders and degrader antibody conjugates (DACs) [4] - The platform leverages hundreds of billions of DEL compound binding signatures from thousands of affinity screens, allowing for the identification of binders for various pharmaceutical targets [4] About Bexobrutideg (NX-5948) - Bexobrutideg is an investigational, orally bioavailable, brain-penetrant small molecule degrader of BTK, currently in a Phase 1 clinical trial for patients with relapsed or refractory B cell malignancies [5] About NRX-0305 - NRX-0305 is a selective, orally bioavailable mutant-specific BRAF degrader showing potent anti-tumor activity in various preclinical models, including those with CNS disease and treatment resistance [6][7] About Aurora A Kinase - Aurora A kinase (AURKA) is frequently overexpressed in various cancers, and Nurix has developed bifunctional targeted protein degraders to address the limitations of traditional inhibitors [7] Company Overview - Nurix Therapeutics focuses on the discovery, development, and commercialization of targeted protein degradation medicines, aiming to improve treatment options for cancer and inflammatory diseases [8] - The company has a clinical-stage pipeline that includes degraders of BTK and inhibitors of CBL-B, along with multiple preclinical programs in collaboration with major pharmaceutical companies [8]